India’s first dengue vaccine, Qdenga, has been introduced with a critical safety warning. The vaccine, developed by the Serum Institute of India, is designed to protect against dengue virus strains 1 and 2. However, it may inadvertently increase the risk of severe dengue in children who have not previously been infected, according to the manufacturer.
The vaccine works by simulating a primary dengue infection in those without prior exposure, which could lead to enhanced immunity against certain strains. However, it does not provide protection against dengue virus strain 3. This limitation means the vaccine may not be effective in all cases.
Health officials emphasize that the vaccine is intended for individuals who have already had a dengue infection. It is not recommended for children who have not been exposed to the virus. The warning highlights the need for careful patient selection to avoid potential complications.
The introduction of Qdenga marks a significant step in the fight against dengue, but its use must be guided by strict medical guidelines to ensure safety (thehindu.com).
